Access Bio Inc
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities wi… Read more
Access Bio Inc - Asset Resilience Ratio
Access Bio Inc (950130) has an Asset Resilience Ratio of 12.52% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how Access Bio Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Access Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩83.51 Billion | 12.52% |
| Total Liquid Assets | ₩83.51 Billion | 12.52% |
Asset Resilience Insights
- Moderate Liquidity: Access Bio Inc has 12.52% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Access Bio Inc Industry Peers by Asset Resilience Ratio
Compare Access Bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Access Bio Inc (2012–2024)
The table below shows the annual Asset Resilience Ratio data for Access Bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.20% | ₩76.60 Million | ₩503.98 Million | +5.16pp |
| 2023-12-31 | 10.04% | ₩69.37 Billion | ₩691.14 Billion | -46.28pp |
| 2022-12-31 | 56.32% | ₩393.51 Million | ₩698.71 Million | +11.00pp |
| 2021-12-31 | 45.32% | ₩168.98 Million | ₩372.85 Million | +15.74pp |
| 2020-12-31 | 29.58% | ₩46.27 Million | ₩156.42 Million | +18.09pp |
| 2019-12-31 | 11.49% | ₩6.92 Million | ₩60.23 Million | +0.77pp |
| 2018-12-31 | 10.72% | ₩9.09 Million | ₩84.82 Million | +3.38pp |
| 2017-12-31 | 7.34% | ₩6.39 Million | ₩87.15 Million | -20.09pp |
| 2016-12-31 | 27.43% | ₩25.02 Million | ₩91.22 Million | +25.47pp |
| 2015-12-31 | 1.96% | ₩1.59 Billion | ₩81.12 Billion | -21.63pp |
| 2014-12-31 | 23.59% | ₩18.62 Billion | ₩78.93 Billion | +21.62pp |
| 2013-12-31 | 1.97% | ₩1.17 Billion | ₩59.19 Billion | +1.22pp |
| 2012-12-31 | 0.75% | ₩219.00 Million | ₩29.09 Billion | -- |